XOMA 3AB: Phase I started

Xoma said NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single doses of XOMA 3AB in abou...